Trial Profile
Single-center, open-label study of GP2017 in healthy male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- 14 Nov 2017 Results from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting according to a Sandoz media release.
- 25 Jan 2017 New trial record